bf/NASDAQ:RIGL_icon.jpeg

NASDAQ:RIGL

Rigel Pharmaceuticals, Inc.

  • Stock

18.72

−4.29%

−2.34

USD last updated 01/08 02:13:39

Last Close

21.06

31/07 22:12

Market Cap

150.83M

Beta: 0.73

Volume Today

148.27K

Avg: 2.73M

PE Ratio

−8.04

PFCF: −5.71

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for t...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -0.20.20.40.62017-08-012019-08-062021-08-032023-08-012024-11-07

    Revenue (Estimate*)

    500M1B1.50B2017-08-012019-08-062021-08-032023-08-012024-11-07

    *Estimate based on analyst consensus